Navigation Links
BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
Date:12/7/2009

ut PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include (1) SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine, (2) Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection, (3) Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents, (4) RypVax(TM) - a recombinant dual antigen vaccine for plague, and (5) a third generation rPA anthrax vaccine.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) unde
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
2. ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement
5. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Gamida Cell Announces Feasibility Study With Weill Cornell Medical College
8. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
9. Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia
10. PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT
11. Ohio Capital Fund Announces Sponsorship of Minority Business Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... Canada (PRWEB) May 23, 2013 ... it is critical to adhere to principles of ... (HSP). , Esteemed speaker Dr. Jeremy Lim, Fellow, ... audience: , ,     Understand the International ... Practice (GCP) and additional regulations for the conduction ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Bed bugs already ... the pests is still ongoing, a report from kmov.com suggested ... for the bed bug treatment. Meanwhile, to be of help, ... from the costly bed bug exterminator service. , ... that AHA has so far spent $35,000 for ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2
... Dec. 11 Myngle,( http://www.myngle.com ), the global ... ICT company at the Europe Unlimited,s European Venture ... EVS is a showcase for ... and new energy entrepreneurs from all over Europe ...
... Inc. (Nasdaq: PBIO ) ("PBI" or the ... have entered into a strategic marketing, distribution, and technology ... companies will: (1) share market data, customer leads, technology ... industry trade shows beginning in 2009; (3) license Omni ...
... HAMBURG, Germany, December 11 Olympus has further,cemented its ... invasive surgery,by signing an exclusive and immediate deal to ... ASC is the sole global,provider of ports for state-of-the-art ... patient,s navel. Olympus is now the exclusive,distributor for the ...
Cached Biology Technology:Myngle Best ICT Company at the European Ventures Summit 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
(Date:5/22/2013)... Irvine, Calif., May 22, 2013 Early screening for ... personal pregnancy testing is for women, thanks to UC ... the American Chemical Society . , After more than ... a way to clearly identify clinically usable markers for ... be detected far sooner, with greater accuracy and at ...
(Date:5/21/2013)... increasingly being considered in the management of natural ... that can help them recognize and respond to ... their lives. , Place-Based Conservation: Perspectives from ... the Pacific Northwest Research Station,s Linda Kruger, can ... The book is published by Springer Verlag and ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... at the University of Pennsylvania School of Medicine have ... a vaccine used to study HIV in macaque monkeys ... (SHIV) than an unmodified vaccine. This multi-year study found ... boosts the effects of a vaccine derived from the ...
... of lead in children,s blood -- amounts well below ... IQ scores, finds a new six-year Cornell study., The ... function in children whose blood-lead levels (BLLs) were below ... of 10 micrograms per deciliter (mcg/dl) -- about 100 ...
... --- Driving down a country road at night your cars ... doesnt move. Depending on your speed and other conditions, chances ... do, its because you are in what is fittingly defined ... published online Nov. 13 by the journal PLoS Biology. ...
Cached Biology News:Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine 2Even minute levels of lead cause brain damage in children 2Northwestern study looks at sensing, movement and behavior 2Northwestern study looks at sensing, movement and behavior 3
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Biology Products: